The Role of ALPK1 in Inhibiting HBV Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting PegIFNα Therapy Response.

Shuang LouJialin WangJiaxuan ChenHaisheng XieHaitao ChenBin ZhouBo ZhangJinlin HouDe-Ke Jiang

Published in: The Journal of infectious diseases (2023)

The anti-HBV effects of ALPK1 through activating JAK-STAT pathway provides a new perspective for CHB therapy. ALPK1_rs35389530 and PGS are potential biomarkers to predict PegIFNα treatment response and may be utilized for optimizing CHB treatment.

Keyphrases

hepatitis b virus
signaling pathway
liver failure
stem cells
combination therapy